CVSI CV Sciences Inc

CV Sciences, Inc. to Host Annual Meeting of Shareholders and Investor Day on August 4, 2018 in San Diego, California

CV Sciences, Inc. to Host Annual Meeting of Shareholders and Investor Day on August 4, 2018 in San Diego, California

Company to Feature Guest Speaker, World-Renowned Neurosurgeon and Sports Medicine Expert Dr. Joseph Maroon

LAS VEGAS, July 10, 2018 (GLOBE NEWSWIRE) -- (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”) will hold its annual meeting of shareholders (AGM) and Investor Day on Saturday, August 4, 2018, at the Company’s corporate office located at 10070 Barnes Canyon Rd., Suite 100, San Diego, CA 92121. On-site registration begins at 9 a.m. PDT, and the meeting will begin at 10 a.m. PDT.

The event will begin with the Company’s AGM, which will include: the election of four directors to serve until the Company’s 2019 AGM, ratification of Tanner as the Company’s independent registered public accounting firm for fiscal year 2018, amendment of the Company’s amended and restated 2013 Equity Incentive Plan, and an amendment to the Company’s certificate of incorporation at the discretion of the board of directors to effect a reverse stock split of all outstanding shares of the Company’s common stock without further authorization of stockholders. 

The Investor Day will feature a corporate presentation from the Company's senior management team who will overview the Company’s business strategy and highlights of its recent (record) earnings quarter, followed by a tour of its new facility.

The Company also welcomes guest speaker, world-renowned neurosurgeon and sports medicine expert, Dr. Joseph C. Maroon, who will speak about the health and nutrition industry and natural alternatives in treating chronic injuries sustained by physical activities primarily in the sports field. In addition, his discussion will highlight his personal interest in healthy living and nutrition and his views on the effectiveness of hemp and CBD in various treatments.

Dr. Maroon obtained his medical and neurosurgical training at Indiana University, Georgetown University, Oxford University in England and the University of Vermont. He conducted extensive research into neurotrauma, brain tumors and diseases of the spine, which has led to many innovative techniques for diagnosing and treating these disorders. His research efforts garnered him numerous awards from various national and international neurological societies.

Attendance is by invitation only as space for the event is limited. Institutional investors, financial analysts, and media interested in attending are encouraged to contact Investor Relations at .

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada, and San Diego, California.  Additional information is available from or by visiting .

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag

Managing Director

IRTH Communications

866-976-4784

EN
10/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CV Sciences Inc

 PRESS RELEASE

CV Sciences, Inc. Reports First Quarter 2022 Financial Results

CV Sciences, Inc. Reports First Quarter 2022 Financial Results SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021;Gross margin of 26.0% for first quarter of 2022, compared to 32.4% for t...

 PRESS RELEASE

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2...

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. The webcast of the conference call will be ...

 PRESS RELEASE

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and Operating Highlights Revenue of $20.0 million for fiscal year 2021, compared to $24.4 million for 2020;Gross margin of 43.0% for fiscal year 2021, compared to 45.1% for 2020;Total cash balance of $1.4 million a...

 PRESS RELEASE

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Result...

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022 SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The ...

 PRESS RELEASE

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line o...

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch